Document is current
Any future updates will be listed below
-
Authors
Moe, Morten Carstens
van Hal, Bas
Melo, Gustavo Barreto https://orcid.org/0000-0001-5765-2008
Jørstad, Øystein Kalsnes https://orcid.org/0000-0003-1259-0653
-
Funding
Funding for this research was provided by:
SJJ Solutions provided funding for the equipment and study drug.
- License Information
-
More Information
Article History
Received: 22 February 2026
Revised: 27 February 2026
Accepted: 6 March 2026
First Online: 19 March 2026
Competing interests
: MCM: Bayer (consultant), Roche (consultant, speaker), and SJJ Solutions (consultant, royalties, speaker). BvH: SJJ Solutions (employee). GBM: 4DMT (research support), Bayer (speaker), EyePoint Pharmaceuticals (research support), SJJ Solutions (consultant, research support). ØKJ: AbbVie (consultant, speaker), Bayer (consultant, speaker), Chiesi Farmaceutici (speaker), Haag-Streit (research support), Horus Pharma (consultant), Roche (consultant, funding), and SJJ Solutions (consultant, royalties, speaker).
